Changes in Adiposity and Cerebrospinal Fluid Biomarkers Following a Modified Mediterranean Ketogenic Diet in Older Adults at Risk for Alzheimer's Disease - PubMed (original) (raw)

Changes in Adiposity and Cerebrospinal Fluid Biomarkers Following a Modified Mediterranean Ketogenic Diet in Older Adults at Risk for Alzheimer's Disease

Tina E Brinkley et al. Front Neurosci. 2022.

Abstract

Background: Ketogenic diets have been used to treat both obesity and neurological disorders, including epilepsy and more recently Alzheimer's disease (AD), likely due to favorable effects on both central and peripheral metabolism. Improvements in body composition have also been reported; however, it is unclear if diet-induced changes in adiposity are related to improvements in AD and related neuropathology.

Purpose: We examined the effects of a Modified Mediterranean Ketogenic (MMK) diet vs. an American Heart Association (AHA) diet on body weight, body composition, and body fat distribution and their association with cerebrospinal fluid (CSF) biomarkers in older adults at risk for AD.

Methods: Twenty adults (mean age: 64.3 ± 6.3 years, 35% Black, 75% female) were randomly assigned to a crossover trial starting with either the MMK or AHA diet for 6 weeks, followed by a 6-week washout and then the opposite diet for 6 weeks. At baseline and after each diet adiposity was assessed by dual-energy x-ray absorptiometry and CSF biomarkers were measured. Linear mixed effect models were used to examine the effect of diet on adiposity. Spearman correlations were examined to assess associations between adiposity and CSF biomarkers.

Results: At baseline there was a high prevalence of overweight/obesity and central adiposity, and higher visceral fat and lower peripheral fat were associated with an adverse CSF biomarker profile. The MMK and AHA diets led to similar improvements in body composition and body fat distribution. Significant correlations were found between changes in adiposity and changes in CSF biomarkers (r's = 0.63-0.92, p's < 0.05), with notable differences by diet. Decreases in body fat on the MMK diet were related to changes in Aβ biomarkers, whereas decreases in body fat on the AHA diet were related to changes in tau biomarkers and cholinesterase activity. Interestingly, increases in CSF Aβ on the MMK diet occurred in those with less fat loss.

Conclusion: An MMK diet leads to favorable changes in body composition, body fat distribution, and CSF biomarkers. Our data suggest that modest weight loss that maximizes visceral fat loss and preserves peripheral fat, may have the greatest impact on brain health.

Clinical trial registration: [www.ClinicalTrials.gov\], identifier [NCT02984540].

Keywords: CSF biomarkers; adiposity; ketogenic diet; mild cognitive impairment; prediabetes; subjective memory complaints.

Copyright © 2022 Brinkley, Leng, Register, Neth, Zetterberg, Blennow and Craft.

PubMed Disclaimer

Conflict of interest statement

HZ has served on scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave and has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche. KB has served as a consultant, on advisory boards, or on data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers. HZ and KB are co-founders of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this manuscript. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Albert M. S., DeKosky S. T., Dickson D., Dubois B., Feldman H. H., Fox N. C., et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7 270–279. 10.1016/j.jalz.2011.03.008 - DOI - PMC - PubMed
    1. Alosco M. L., Duskin J., Besser L. M., Martin B., Chaisson C. E., Gunstad J., et al. (2017). Modeling the relationships among late-life body mass index, cerebrovascular disease, and Alzheimer’s disease neuropathology in an autopsy sample of 1,421 subjects from the national Alzheimer’s coordinating center data set. J. Alzheimers Dis. 57 953–968. 10.3233/jad-161205 - DOI - PMC - PubMed
    1. American Diabetes Association (2015). Standards of medical care in diabetes-2015 abridged for primary care providers. Clin. Diabetes 33 97–111. 10.2337/diaclin.33.2.97 - DOI - PMC - PubMed
    1. Amini M. R., Aminianfar A., Naghshi S., Larijani B., Esmaillzadeh A. (2021). The effect of ketogenic diet on body composition and anthropometric measures: a systematic review and meta-analysis of randomized controlled trials. Crit. Rev. Food Sci. Nutr. 62 1–14. 10.1080/10408398.2020.1867957 - DOI - PubMed
    1. Atti A. R., Palmer K., Volpato S., Winblad B., De Ronchi D., Fratiglioni L. (2008). Late-life body mass index and dementia incidence: nine-year follow-up data from the Kungsholmen project. J. Am. Geriatr. Soc. 56 111–116. 10.1111/j.1532-5415.2007.01458.x - DOI - PubMed

LinkOut - more resources